The composition of triglycerides of the axillary sebaceous glands in 10 patient, with osmidrosis and 10 patients with hyperhidrosis was analyzed by high pressure liquid chromatography. Sebaceous glands were isolated and dissected by Kellum's method, and lipids were extracted by Folchs method. Individual triglycerides were separated by high pressure liquid chromatography and fatty acid composition of triglycerides was analyzed by gas-liquid chromatography. A number of individual triglycerides were identified: Fraction 1 consisted of dimyristoarachidonin, dilinoleioarachidonin, and myristol inoleioarachidonin, fraction 2 was trilinolein, fraction 3 was dilinoleioolein, fraction 4 was dilinoleiopalmitin, fraction 5 consisted of dioleiolinolein, dipalmitolinoleiri, and palmitooleilinolein. In osmidrosis patients, cornpositions of fraction 1, 2, 3, 4, and 5 were 5, 4%. 18.5% 29.5% 32.0% 14.1% of total triglycerides, respectively. In hyperhidrosis patients, cornpositions of fraction 1, 2, '3, 4, and 5 were,5, 9%, 20. 6%, 30. 9% 32. 1%, 14. 5% of total triglycericles, resectively. There were no differences in composition of triglycerides of sekaceous glands between osmidrosis patients and hyperhidrosis patients and hyperhi.frosis patients.
Chromatography, Gas ; Chromatography, Liquid ; Humans ; Hyperhidrosis ; Sebaceous Glands* ; Soil* ; Triglycerides*

Background/Aims: Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients. Methods: We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan’s cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray’s cumulative incidence and Cox subdistribution hazards models to analyze HCC development. Results: Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not using metformin had a 51% increased risk of HCC compared to non-DM patients, while HLP patients on statins had a 50% reduced risk compared to those without HLP. The 5-year HCC incidence was significantly higher for metformin non-users (16.5%) versus non-DM patients (11.3%; adjusted sub-distribution hazard ratio [aSHR]=1.51; P=0.007) and metformin users (3.1%; aSHR=1.59; P=0.022). Statin use in HLP patients correlated with a lower HCC risk (3.8%) compared to non-HLP patients (12.5%; aSHR=0.50; P<0.001). Notably, the increased HCC risk associated with non-use of metformin was primarily seen in non-cirrhotic patients, whereas statins decreased HCC risk in both cirrhotic and non-cirrhotic patients. Conclusions Metformin and statins may have a chemopreventive effect against HCC in CHC patients who failed antiviral therapy. These results support the need for personalized preventive strategies in managing HCC risk.